Dosing and uses of Iquix, Quixin (levofloxacin ophthalmic)
Adult dosage forms and strengths
ophthalmic solution
- 0.5%
Bacterial Conjunctivitis
Solution 0.5%
1-2 gtt in affected eye(s) q2hr on days 1-2, while awake, up to 8 times/day, THEn
1-2 gtt q4hr; not to exceed four times daily on days 3-7
Pediatric dosage forms and strengths
ophthalmic solution
- 0.5%
- 1.5%
Bacterial Conjunctivitis
Ophth soln 0.5%
<1 year: Safety & efficacy not established
1 year or older: 1-2 gtt in affected eye(s) q2hr on days 1-2, while awake, up to 8 times/day, THEN 1-2 gtt q4hr; not to exceed QID on days 3-7
Iquix, Quixin (levofloxacin ophthalmic) adverse (side) effects
Frequency not defined
Transient decrease in vision
Transient ocular burning
Ocular pain or discomfort
Foreign body sensation
Headache
Fever
Pharyngitis
Photophobia
Allergic reactions
Lid edema
Ocular dryness
Ocular itching
Warnings
Contraindications
Hypersensitivity to quinolones or any component
Cautions
May result in overgrowth of nonsusceptible organisms, including fungi
Some pts may require slit-lamp biomicroscopy & fluorescein staining
serious hypersensitivity reactions with systemic use of fluoroquinolones reported; use caution
Safety and efficacy on children
Pregnancy and lactation
Pregnancy category: C
Lactation: May be distributed into milk; use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Iquix, Quixin (levofloxacin ophthalmic)
Mechanism of action
Inhibits DNA topoisomerase (ATP-hydrolyzing), a type II DNA topoisomerase commonly referred to as DNA-gyrase, in susceptible organisms; promotes breakage of DNA strands, inhibits relaxation of supercoiled DNA; inhibits DNA repair and recombination
Pharmacokinetics
Absorption: Minimal with ophthalmic use
